Literature DB >> 6141518

Effects of antidepressant drugs on histamine-H1 receptors in the brain.

H Hall, S O Ogren.   

Abstract

The histamine-H1 receptor blocking properties of a number of structurally different antidepressant drugs have been evaluated using a 3H-mepyramine binding assay and a guinea-pig ileum preparation. The tricyclic antidepressants all inhibited the histamine-H1 receptor. Some newer antidepressant drugs, such as zimelidine and nomifensine were devoid of activity while others, such as iprindole and mianserin were very potent. It is concluded that antagonistic effects on the histamine-H1 receptor is not associated with the therapeutic efficacy in depression, but may contribute to the sedative effects of the antidepressant drugs.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6141518     DOI： 10.1016/0024-3205(84)90494-6

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  9 in total

Review 1.  Histamine receptors in the central nervous system.

Authors:  H Timmerman
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

2.  Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor.

Authors:  D R Thomas; D R Nelson; A M Johnson
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 3.  Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  R J Milne; K L Goa
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 4.  Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.

Authors:  C Sánchez; J Hyttel
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

5.  Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.

Authors:  C Sánchez; P B F Bergqvist; L T Brennum; S Gupta; S Hogg; A Larsen; O Wiborg
Journal:  Psychopharmacology (Berl)       Date:  2003-04-26       Impact factor: 4.530

Review 6.  Behavioural effects of histamine and its antagonists: a review.

Authors:  J M White; G R Rumbold
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine H1, muscarine cholinergic and alpha 1-adrenergic receptors.

Authors:  J Herrstedt; J Hyttel; J Pedersen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.

Authors:  Robert L Findling; Shawn A Candler; Azmi F Nasser; Stefan Schwabe; Chungping Yu; Jennie Garcia-Olivares; Welton O'Neal; Jeffrey H Newcorn
Journal:  CNS Drugs       Date:  2021-05-18       Impact factor: 5.749

9.  Differences in Cerebral Distribution between Imipramine and Paroxetine via Membrane Transporters at the Rat Blood-Brain Barrier.

Authors:  Shin-Ichi Akanuma; Myeongrae Han; Yuka Murayama; Yoshiyuki Kubo; Ken-Ichi Hosoya
Journal:  Pharm Res       Date:  2022-02-02       Impact factor: 4.200
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.